The Angiogenesis Foundation

The Angiogenesis Foundation, is a United States 501(c)(3) nonprofit organization established in 1994 for the study of angiogenesis. The foundation developed a therapy for canine cancer, called the Navy Protocol. This treatment works by starving the tumor of its blood supply.^[1] In 2004, they helped publicly launch the first antiangiogenic therapy for cancer, bevacizumab, starting with colorectal cancer.^[2] In 2010, the president and co-founder of the Angiogenesis Foundation, William Li, gave a well-received presentation at the TED conference on cancer prevention through antiangiogenic nutrition.^[3]

The Angiogenesis Foundation

Company type	Non-profit
Founded	1994 in Cambridge, MA
Founder	William W. Li, MD and Vincent W. Li, MD (co-founders)
Headquarters	Cambridge, MA, U.S.
Revenue	1,772,286 United States dollar (2017)
Total assets	359,298 United States dollar (2022)
Website	angio.org

Co-founder Dr. William Li won the 2024 Dr. Andrew von Eschenbach Award for his work in angiogenesis.^[4]